Clinical trials: Head and Neck Squamous Cell Carcinomas
Squamous Cell Tumors of the Head and Neck (HNSCC)
Development of Patient Derived Xenografts (PDXs) and Analysis of Tyrosine Kinase Receptor Expression in Patients With Squamous Cell Head and Neck Cancer (HNSCC) to Study Resistance Mechanisms Induced by Standard Therapy
Protocol TitleDevelopment of Patient-Derived Xenografts (PDXs) and analysis of tyrosine kinase receptor expression in patients with Head and Neck Squamous Cell Carcinoma (HNSCC) to study resistance mechanisms induced by standard…
- Trial name
- SPAR (NCT07471009)
- Where
- Italy
- Volunteers
- 120 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Head and Neck Squamous Cell Carcinoma (HNSCC)
Optimizing Response to Immunotherapy With Online Adaptive Pulsed Radiotherapy in Incurable Head and Neck Cancers
The ORION study will evaluate a novel treatment approach for patients with recurrent, metastatic, oligometastatic, or locoregionally incurable head and neck squamous cell carcinoma (HNSCC).
- Trial name
- ORION (NCT07888816)
- Testing
- Pulsed Adaptive Radiotherapy Combined with Pembrolizumab with or without chemotherapy
- Where
- Canada
- Volunteers
- 48 people
- Sponsor
- University Health Network, Toronto
Neoplasms, Hiv
A Multilevel Intervention to Improve Timely Cancer Detection and Treatment Initiation
This study evaluates whether the Potlako+ intervention of community education, clinical provider support, and patient navigation can improve access to cancer case for patients presenting with symptoms of cancer.
- Conditions
- Neoplasms, Hiv, Cervical Cancer, Breast Cancer
- Trial name
- Potlako+ (NCT04141449)
- Testing
- Potlako intervention, Enhanced care
- Where
- Botswana
- Volunteers
- 874 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Breast Cancer, Ovarian Cancer
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
A Phase 1, open label, dose escalation and expanded cohort study of P-MUC1C-ALLO1 in adult subjects with advanced or metastatic epithelial derived solid tumors, including but not limited to the tumor types listed below.
- Conditions
- Breast Cancer, Ovarian Cancer, Non Small Cell Lung Cancer, Colorectal Cancer
- Trial name
- NCT05239143
- Testing
- P-MUC1C-ALLO1 CAR-T cells, Rimiducid
- Where
- 14 sites in United States
- Volunteers
- 180 people
- Sponsor
- Poseida Therapeutics, Inc.
Squamous Cell Carcinoma, Esophageal Cancer
Teripalimab Plus Chemotherapy in Local Advanced Esophageal Cancer
The prognosis of locally advanced esophageal squamous cell carcinoma is poor,the role of chemotherapy as neoadjuvant therapy in locally advanced esophageal cancer has been established, which can convert some unresectable…
- Conditions
- Squamous Cell Carcinoma, Esophageal Cancer, Perioperative Period
- Trial name
- NCT03985670
- Testing
- teripalimab plus chemotherapy, chemotherapy plus teripalimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Henan Cancer Hospital
Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma
Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma
In this study, patients with recurrent or metastatic head and neck squamous cell carcinoma will receive first line treatment with olaparib, pembrolizumab, and carboplatin.
- Trial name
- NCT04643379
- Testing
- Olaparib, Pembrolizumab, Carboplatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Washington University School of Medicine
Recurrent and/or Metastatic Platinum-refractory SCCHN
Nivolumab in Recurrent and/or Metastatic SCCHN
Recurrent and/or metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) are a common clinical situation and although this group of patients has very heterogeneous disease characteristics, they share a dismal prognosis…
- Trial name
- TopNIVO (NCT03226756)
- Testing
- Nivolumab Injection
- Where
- 18 sites in France
- Volunteers
- 351 people
- Sponsor
- UNICANCER
Esophageal Squamous Cell Carcinoma
Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC
In this prospective trial, patients demonstrating clinical complete response (cCR) as determined by a standard response assessment protocol (incorporating clinical and molecular diagnostic methods) will be offered organ-sparing…
- Trial name
- NCT06861894
- Testing
- Adebrelimab and nab-paclitaxel and carboplatin, Radiation, standard oesophagectomy
- Where
- China
- Volunteers
- 164 people
- Sponsor
- Zhigang Li
Esophageal Cancer, Esophageal Adenocarcinoma
Preoperative Image-guided Identification of Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer
Rationale: For locally advanced esophageal cancer the standard treatment consists of 5 weeks of neoadjuvant chemoradiotherapy (nCRT) followed by surgery.
- Conditions
- Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms
- Trial name
- PRIDE (NCT03474341)
- Testing
- MRI, PET-CT, Endoscopy
- Where
- 4 sites in Netherlands
- Volunteers
- 200 people
- Sponsor
- UMC Utrecht
Head and Neck Cancers
A Prospective, Multicenter, Multicohort Phase II Study: Evaluating the Efficacy and Safety of Preoperative Neoadjuvant Treatment With a PD-1 Inhibitor in Combination With Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Squamous Cell Carcinoma
Head and neck squamous cell carcinoma (HNSCC) refers to a series of tumors that occur in the head and neck region, including the oral cavity, pharynx, larynx, nasal cavity, paranasal sinuses, thyroid gland, and salivary glands.
- Trial name
- NCT06894459
- Testing
- Pembrolizumab, Cisplatin, Nab-paclitaxel
- Volunteers
- 180 people
- Sponsor
- Beijing Tongren Hospital
Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms
Spatial MSC Index for Predicting Anti-PD-1 Efficacy in Esophageal Cancer
The intratumoral microbiota is a key modulator of the tumor immune microenvironment. This study aims to clinically validate a novel, AI-driven digital pathology biomarker-the Microbial-Sensory Coupling (MSC) index-which measures…
- Trial name
- NCT07745322
- Where
- China
- Volunteers
- 270 people
- Sponsor
- Peking University Cancer Hospital & Institute
Oligometastatic Squamous Cell Carcinoma of the Head and Neck
Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer
This is a randomized open-label multicentre phase III superiority study of the effect of adding SABR to the standard of care treatment pembrolizumab on progression free survival in patients with oligometastases of a squamous cell…
- Trial name
- PROLoNg (NCT05815927)
- Testing
- Pembrolizumab, stereotattic ablation radiotherapy (SABR)
- Where
- 30 sites in Belgium, Italy and 2 more
- Volunteers
- 200 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Esophageal Squamous Cell Carcinoma
KN046 in Subjects With Late Stage Esophageal Squamous Cell Carcinoma
This is an open-label, multi-center, single arm study to evaluate the efficacy, safety and tolerability of KN046 in subjects with advanced unresectable or metastatic esophageal squamous cell carcinoma (ESCC).
- Trial name
- NCT03925870
- Testing
- KN046
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Gastric Cancer, Renal Cell Carcinoma
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
The purpose of this study is to test the safety and tolerability of HFB200301 as a single agent and in combination with tislelizumab in patients with advanced cancers. There are two parts in this study.
- Conditions
- Gastric Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma
- Trial name
- NCT05238883
- Testing
- HFB200301, Tislelizumab
- Where
- 10 sites in United States, Spain
- Volunteers
- 72 people
- Sponsor
- HiFiBiO Therapeutics
Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer
Phase I/II trial to study the effectiveness of combining erlotinib with docetaxel in treating patients who have locally advanced, recurrent, or metastatic head and neck cancer.
- Conditions
- Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity
- Trial name
- NCT00055770
- Testing
- erlotinib hydrochloride, docetaxel, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Superficial Esophageal Cancer, Oesophageal Adenocarcinoma
Multicenter Prospective Cohort on Esophageal Endoscopic Submucosal Dissection
In France in 2018, there were an estimated 2,074 new cases of esophageal adenocarcinoma and 3,224 cases of squamous cell carcinoma.
- Conditions
- Superficial Esophageal Cancer, Oesophageal Adenocarcinoma, Oesophageal Squamous Cell Carcinoma, Barretts Esophagus With Dysplasia
- Trial name
- FEO (NCT07343869)
- Where
- France
- Volunteers
- 750 people
- Sponsor
- Société Française d'Endoscopie Digestive
Esophageal Squamous Cell Carcinoma, Adenocarcinoma Of Esophagus
Proton Beam Therapy to Treat Esophageal Cancer
Assess progression-free survival and overall survival of proton beam therapy (PBT) for patients with resectable vs. unresectable esophageal cancer, and to assess patient-reported outcomes of PBT for esophageal cancer at 6 months…
- Trial name
- NCT02023541
- Testing
- Proton beam therapy
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Washington University School of Medicine
Squamous Cell Carcinoma of Head and Neck
Dendritic Cell Vaccine for Head and Neck Cancer
This research study is testing a new treatment of cancer of the head and neck. Purpose This research study is being done to: 1. Test the safety of the experimental cancer vaccine made of dendritic cells.
- Trial name
- Dendritic (NCT00492947)
- Testing
- dendritic cell vaccine
- Where
- United States
- Sponsor
- University of Maryland, Baltimore
Head and Neck Squamous Cell Carcinoma (HNSCC)
A Study for Identification of Immune Determinants for Response to Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
A study for identification of immune determinants for response to Nivolumab in Recurrent /Metastatic HNSCC(Head and neck squamous cell carcinoma) patients.
- Trial name
- NCT04603248
- Testing
- Nivolumab
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Yonsei University
Head and Neck Cancer
Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Stage III or Stage IV Head and Neck Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00005814
- Testing
- cetuximab, cisplatin, radiation therapy
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.